Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Human IgG1 (Fab-His) Isotype Control Antibody (HyHEL-10)

Catalog #:   RHJ92802 Specific References (50) DATASHEET
Host species: Human
Isotype: IgG1 (Fab-His)
Applications: FCM, Isotype Control, In vivo Control
Overview

Catalog No.

RHJ92802

Host species

Human

Isotype

IgG1 (Fab-His)

Clonality

Monoclonal

Target

Human IgG1 (Fab-His)

Concentration

0.83 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Purified by Nickel column.

Applications

FCM, Isotype Control, In vivo Control

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

HyHEL-10

Data Image
  • SDS-PAGE
    SDS PAGE for Human IgG1 (Fab-His) Isotype Control Antibody (HyHEL-10)
References

Immune response to and virological profile of SARS-CoV-2 before and after symptom onset in individuals vaccinated with inactivated COVID-19 vaccines., PMID:40530661

Prevalence of dengue in febrile patients in Peru: A systematic review and meta-analysis., PMID:40526741

Negative associations of age and lifestyle factors with the antibody response to the COVID-19 vaccine BNT162b2 in health workers from Spain., PMID:40519918

Patrolling monocytes mediate virus neutralizing IgG effector functions: beyond neutralization capacity., PMID:40510351

Leveraging the Polymorphism of the Merozoite Surface Protein 2 (MSP2) to Engineer Molecular Tools for Predicting Malaria Episodes in a Community., PMID:40508084

Rapid detection of SARS-CoV-2 antigen based on IgG colloidal gold immunochromatographic strip., PMID:40506633

Detectable SARS-CoV-2 specific immune responses in recovered unvaccinated individuals 250 days post wild type infection., PMID:40498720

Seroprevalence of Toxoplasmosis and the Possible Role of C-Reactive Protein in the Pathogenesis of Myocardial Infarction in Patients from Iraq; A Case Control Study., PMID:40498362

Profiling of Anti-glycan IgA and IgG in Oral Fluid Using a Glycan Microarray., PMID:40498306

Efficacy of Subcutaneous Immunoglobulin in the Postoperative Management After Pediatric Living Donor Liver Transplantation., PMID:40495281

Evaluating the Effects of 60°C Heating for 90 Min on Bacterial Pathogen Viability and IgG Concentration in Bovine Colostrum., PMID:40493565

Kinetic of the Maternally-Derived Anti-Parvovirus IgG During the Neonatal Period: A Quantitative Assessment., PMID:40493541

Treatment Patterns and Disease Burden of Juvenile Myasthenia Gravis in the United States: A Cohort Study Using Health Care Claims Databases., PMID:40489715

Prevalence, knowledge, attitudes, and practices regarding Chagas disease in Guanare, Venezuela: a cross-sectional study., PMID:40484948

Serological analysis of gluten-related antibodies in idiopathic neuropathies and cerebellar ataxia., PMID:40481865

Immune age is correlated with decreased TCR clonal diversity and antibody response to SARS-CoV-2., PMID:40481111

Defining Aedes aegypti density thresholds for preventing human arboviral infections., PMID:40480602

Impact of Heat Treatment on the Allergenic Potential of Penaeus chinensis TM: A Comprehensive Analysis of Structural Changes, Molecular Dynamics, Digestibility, Allergenicity and Gut Microbiota Alterations., PMID:40478200

Development of an oral gut-targeted rabies virus-like particles (RVLPs) vaccine with mucosal immune adjuvant LTB via delivering of localized-release microparticles., PMID:40476513

Avidity of pertussis toxin antibodies following vaccination with genetically versus chemically detoxified pertussis toxin-containing vaccines during pregnancy., PMID:40475765

Cumulative IgG reagent carryover detected in carryover evaluation of urinary total protein testing using AU5800 biochemistry analyzer., PMID:40469573

Seroepidemiological survey of the population 10 years after the implementation of the varicella vaccine 2-dose immunization strategy., PMID:40464766

Tracking the dynamics of antibody production against the SARS-CoV-2 virus after two doses of the mRNA vaccine BNT162b2., PMID:40461246

Decade-long protection of the mumps vaccine: Insights from a large-scale serological study., PMID:40460365

12-Month Outcomes of a Prospective Randomized Trial Investigating Effects of IVIG on Top of rATG Versus rATG Alone in Pre-Sensitized Kidney Transplant Recipients: The INHIBIT Study., PMID:40458542

Parameter-Optimized Fabrication of Submicron Nanoelectrospray Emitters for Enhanced Native Mass Spectrometry., PMID:40456619

Assessing COVID IGRA and IgG antibodies in healthcare workers post vaccination., PMID:40452527

Prevalence of epsilon toxin-producing Clostridium perfringens isolates among patients with multiple sclerosis and neuromyelitis optica spectrum disorder in Iran., PMID:40450217

Analysis of Increased False-Positive ELISA Results for HIV in the Blood of Donors Infected with SARS-CoV-2., PMID:40448880

Preparation of a Brucella multiepitope fusion protein based on bioinformatics and its application in serological diagnosis of human brucellosis., PMID:40447804

Detection of moderate to high antiphospholipid antibodies by chemiluminescence meets 2023 APS classification criteria., PMID:40447711

Immune persistence after 5 years of vaccination by Vi-DT vaccine among children below 2 years: Result from long-term observational study., PMID:40446606

Wb5, a novel biomarker for monitoring efficacy and success of mass drug administration programs for Wuchereria bancrofti elimination., PMID:40446061

The prevalence and associated risk factors of post-transplant Toxoplasma gondii infection among kidney transplant recipients and patients with uremia in Central-southern China., PMID:40446014

Comparative immune response of Typbar TCV® (typhoid conjugate vaccine) in extremes of age: An Indian experience., PMID:40445123

High-Efficient and Controllable Purification of Protein by Cyclic Injection in an Orthogonal Micro-Free-Flow Electrophoresis., PMID:40442025

Adults in Ghana generate higher and more durable neutralising antibody titres following primary course COVID-19 vaccination than matched UK adults: The HERITAGE Study., PMID:40437463

Systems serology-based comparison of humoral immune responses induced by liposome or aluminum hydroxide adjuvanted SARS-CoV-2 spike protein., PMID:40436929

Incidence of SARS-CoV-2 reinfection among blood donors from two Brazilian states in the post-vaccination period: a prospective cohort study., PMID:40435110

Chlamydia muridarum mutant CM-pGP3S as a novel attenuated live rectal vaccine protects against genital tract infection., PMID:40433661

Development of a Diagnostic Algorithm for Epstein-Barr Virus-Related Diseases: A Retrospective Observational Study., PMID:40432357

Long-Term Dynamics of SARS-CoV-2 Variant-Specific Neutralizing Antibodies Following mRNA Vaccination and Infection., PMID:40431687

Impact of Vaccine-Elicited Anti-Spike IgG4 Antibodies on Fc-Effector Functions Against SARS-CoV-2., PMID:40431678

Individuals Infected with SARS-CoV-2 Prior to COVID-19 Vaccination Maintain Vaccine-Induced RBD-Specific Antibody Levels and Viral Neutralization Activity for One Year., PMID:40431652

Evaluating SARS-CoV-2 T Cell Immunity in COVID-19-Naive Vaccinated Individuals with and Without Spike Protein IgG Antibodies., PMID:40430736

Serum Antibody Titres Against Porphyromonas gingivalis Fim A in Patients with Periodontitis with and Without Diabetes Mellitus Type 2., PMID:40429868

Integrated in-silico design and in vivo validation of multi-epitope vaccines for norovirus., PMID:40426240

Characterizing local antibody responses in the muscle of inclusion body myositis patients., PMID:40424896

PcrV in an intranasal adjuvanted tobacco mosaic virus conjugate vaccine mediates protection from Pseudomonas aeruginosa via an early Th1/Th17 skewed localized and systemic immune response., PMID:40424705

Effective cellular and neutralizing immunity against SARS-CoV-2 after mRNA booster vaccination is associated with pDC and B cell activation., PMID:40421016

Datasheet
$ 260
Product specifications
100 μg 260 1 mg 1040

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Human IgG1 (Fab-His) Isotype Control Antibody (HyHEL-10) [RHJ92802]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only